Ampion demonstrated an improvement in all-cause mortality in COVID-19 patients compared to standard of care (SOC). A lower all-cause mortality rate of 8% is observed for the Ampion treatment group, compared to 21% in standard of care alone.
Patients who received Ampion required less hospitalization time. The average hospital length of stay was 7 days for the Ampion group compared to 11 days for standard of care patients.
Patients who received Ampion required less oxygen than standard of care alone, and 86% of Ampion patients were stable or had improvement compared to 75% of SOC patients.
More patients who received Ampion were stable or had improvement on a scale of clinical improvement compared to standard of care alone. By day 5, 86% of patients who received Ampion were stable or had improvement compared to 75% of standard of care patients. This trend in improvement with Ampion treatment is noted as early as day 2 and continues to day 5.
Adverse events were the same between Ampion and standard of care, and no drug-related serious adverse events have been reported.
In commenting on the preliminary positive results in the AP-014 Phase I clinical trial of inhaled Ampion, Dr. David Cornutt, MD, Chairman, Department of Emergency Medicine, Regional West Health Services, and a Medical Monitor on the study, said, "The scientific findings we have reviewed thus far are fascinating and very encouraging. While we are still looking at preliminary data from a small sample size, the safety signals look strong, and I look forward to moving into the efficacy phases to come."
Good Day Changes, where have you been? Here is something sinister but I believe you posted a link about the neuro-regenerative efficacy of VIP that could restore degenerated brain function due to a stroke. Also you had an article on the effect of COVID19 on the brain, right? Do you still have that link? Spooky stuff: https://www.nytimes.com/2021/03/22/health/covid-psychosis.html
News 
Market Data 
Discover 
